Fiera Capital Corp Sells 17,917 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Fiera Capital Corp lessened its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 2.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 795,157 shares of the company’s stock after selling 17,917 shares during the quarter. Fiera Capital Corp’s holdings in Immunocore were worth $28,888,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new position in Immunocore in the 2nd quarter worth approximately $42,000. Osaic Holdings Inc. lifted its holdings in shares of Immunocore by 117.4% during the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares during the last quarter. Finally, State of Tennessee Department of Treasury acquired a new position in shares of Immunocore during the second quarter worth approximately $132,000. 84.50% of the stock is currently owned by institutional investors.

More Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst and institutional support: multiple brokers still carry buy/overweight views and the consensus average price target (~$60.90) sits well above the current market level, which can underpin upside if clinical or commercial progress resumes. MarketBeat IMCR Coverage
• Positive Sentiment: High institutional ownership (~84.5%): large, stable holders (Primecap, Bellevue, Tang Capital, Millennium, Armistice) can reduce free float and provide support over the medium term as long-term investors remain committed. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: very high current and quick ratios (~6.0) reduce short-term solvency risk but are unlikely to drive near-term share moves absent new catalysts.
• Neutral Sentiment: Short-interest data appears inconsistent: the recent report shows effectively 0 shares short (and 0 days to cover), which is likely a reporting anomaly and should be treated cautiously rather than interpreted as a market signal.
• Neutral Sentiment: Lower-than-average intraday volume can amplify price moves on either positive or negative news; monitor volume for conviction on any follow-through.
• Negative Sentiment: Clustered insider selling: CEO Bahija Jallal sold 11,474 shares (~48% reduction in her stake) and several other senior insiders (David Berman, John Goll, Tina Leger) also sold large portions on the same day—a development that commonly pressures sentiment and can trigger short‑term selling. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Immunocore Price Performance

Shares of Immunocore stock opened at $32.68 on Friday. The firm has a market cap of $1.65 billion, a P/E ratio of -57.33 and a beta of 0.78. The firm’s 50-day simple moving average is $33.81 and its 200-day simple moving average is $34.30. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $40.71. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00.

Insider Buying and Selling at Immunocore

In related news, CEO Bahija Jallal sold 11,474 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the completion of the transaction, the chief executive officer owned 12,343 shares in the company, valued at $399,296.05. This trade represents a 48.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Leger Tina Amber St sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $32,350.00. Following the completion of the sale, the insider directly owned 1,119 shares in the company, valued at approximately $36,199.65. This represents a 47.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 19,137 shares of company stock valued at $619,082. 10.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IMCR. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Morgan Stanley upped their price objective on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Mizuho set a $38.00 target price on shares of Immunocore in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company started coverage on Immunocore in a report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.90.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.